Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Document Type
Journal Article
Publication Date
10-1-2017
Journal
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
Volume
25
Issue
10
Inclusive Pages
3217-3224
DOI
10.1007/s00520-017-3732-6
Keywords
Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Bortezomib; Female; Humans; Incidence; Male; Middle Aged; Multiple Myeloma; Peripheral Nervous System Diseases; Recurrence; Retreatment; Retrospective Studies; Risk Factors; Severity of Illness Index; Treatment Outcome
APA Citation
Vidisheva, A., Wang, J., Spektor, T., Bitran, J., Lutzky, J., Tabbara, I., Ye, J., Ailawadhi, S., Stampleman, L., Steis, R., Moezi, M., Swift, R., Maluso, T., Udd, K., Eshaghian, S., Nassir, Y., & Berenson, J. (2017). Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 25 (10). http://dx.doi.org/10.1007/s00520-017-3732-6
Peer Reviewed
1